Keyphrases
Inflammation
100%
Therapeutic Target
50%
Heart Failure with Preserved Ejection Fraction (HFpEF)
50%
Cardiovascular Disease
50%
Metformin
50%
Type 2 Diabetic Patients
50%
Left Ventricular Hypertrophy
50%
Left Ventricular Remodeling
50%
Dapagliflozin
50%
Heart Failure
34%
Global Longitudinal Strain
28%
Type 2 Diabetes Mellitus (T2DM)
23%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
22%
LV Mass
21%
Placebo
21%
Interleukin-1β
21%
C-reactive Protein
21%
Inflammatory Markers
21%
Pathophysiology
17%
Cardiovascular Effects
15%
Tumor Necrosis Factor-α
14%
Neutrophil-to-lymphocyte Ratio
14%
Treatment Strategy
10%
Potential Therapeutic Strategies
10%
Clinical Outcomes
10%
Targeted Treatment
10%
Reduced Ejection Fraction
10%
Unmet Needs
10%
Evidence-based Treatment
10%
Glycemic Control
8%
Glucagon-like
8%
Metformin Use
8%
Randomized Clinical Trial
8%
Clinical Trial Data
8%
Observational Data
8%
Metabolic Properties
8%
Cardiovascular Outcome Trials
8%
Anti-inflammatory Effect
8%
Cardiovascular Outcomes
8%
A1 Receptor
8%
Receptor Agonist
8%
Interleukin-6
7%
Clinical Data
7%
Cardiac Remodeling
7%
Beneficial Effects
7%
Symptomatic Heart Failure
7%
Reverse Remodeling
7%
Interleukin-10
7%
Cardiac Magnetic Resonance Imaging (cMRI)
7%
Plasma Samples
7%
Cotransporter
7%
Preclinical Data
7%
Systemic Inflammation
7%
End of Treatment
7%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammation
100%
Non Insulin Dependent Diabetes Mellitus
64%
Clinical Study
60%
Preclinical Study
50%
Heart Failure with Preserved Ejection Fraction
50%
Metformin
50%
Dapagliflozin
50%
Heart Left Ventricle Hypertrophy
50%
Heart Ventricle Remodeling
50%
Cardiovascular Disease
50%
Congestive Heart Failure
38%
Sodium Glucose Cotransporter 2 Inhibitor
19%
Placebo
18%
C Reactive Protein
18%
Interleukin 1
18%
Pathophysiology
16%
Tumor Necrosis Factor
12%
Antiinflammatory Activity
7%
Randomized Clinical Trial
7%
Glucagon Like Peptide 1 Receptor Agonist
7%
Cotransporter
6%
Interleukin 6
6%
Interleukin 10
6%
Medicine and Dentistry
Clinical Study
60%
Glycon
50%
Cardiovascular Disease
50%
Heart Failure with Preserved Ejection Fraction
50%
Congestive Heart Failure
20%
Cardiovascular System
14%
Maturity Onset Diabetes of the Young
14%
Pathophysiology
10%
Ejection Fraction
10%
Randomized Clinical Trial
7%
Glycemic Control
7%
Antiinflammatory Activity
7%
Sodium Glucose Cotransporter 2 Inhibitor
7%
Glucagon-Like Peptide-1 Agonist
7%
Cardiovascular Effect
7%